Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/28/2007WO2007024961A3 Bazedoxifene acetate formulations and manufacturing process thereof
06/28/2007WO2007023325A3 Controlled release pharmaceutical composition containing carvedilol
06/28/2007WO2007022938A3 Compounds
06/28/2007WO2007019540A3 Controlled release alpha-lipoic acid formulation with an inositol compound
06/28/2007WO2007019224A3 Formulations and methods for enhancing the transdermal penetration of a drug
06/28/2007WO2007019221A3 Pharmaceutical compositions of silicon-containing substituted adenosine nucleoside amide analogs
06/28/2007WO2007017219A3 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
06/28/2007WO2007016563A3 Alcohol resistant pharmaceutical formulations
06/28/2007WO2007014943A3 Therapy for neurological diseases
06/28/2007WO2007014250A3 Abl kinase inhibition
06/28/2007WO2007013480A3 Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
06/28/2007WO2007009800A3 Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent
06/28/2007WO2007008927A3 Bioresorbable composition for repairing skeletal tissue
06/28/2007WO2007007905A3 Carboxamide compound and use of the same
06/28/2007WO2007005940A3 Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
06/28/2007WO2007005541A3 Small molecule inhibitors against west nile virus replication
06/28/2007WO2007005531A3 Alkenyldiarylmethanes, fused analogs and syntheses thereof
06/28/2007WO2007004226A3 Compositions and methods for treatment of male erectile dysfunction (ed)
06/28/2007WO2007002912A3 Anti-proliferative compounds, compositions, and methods of use thereof
06/28/2007WO2007002781A3 Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
06/28/2007WO2007002314A3 Polymorphic forms of tegaserod maleate
06/28/2007WO2007000779A3 Pharmaceutical sustained release compositions and processes thereof
06/28/2007WO2006138427A3 Combretastatin analogs with tubulin binding activity
06/28/2007WO2006135712A3 (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
06/28/2007WO2006132739A3 Novel chemical compounds
06/28/2007WO2006122309A3 Stable lyophilized anthracycline glycosides
06/28/2007WO2006120213A3 Novel use of liver x receptor agonists
06/28/2007WO2006117404A3 Topical use of radical capturing substances for antipyretic treatment
06/28/2007WO2006116526A3 Polymorph form ii of tanaproget
06/28/2007WO2006116353A3 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
06/28/2007WO2006115743A3 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
06/28/2007WO2006115713A3 Eutectic blends containing a water soluble vitamin derivative
06/28/2007WO2006114065A3 Use of compounds to inhibit neoplasia
06/28/2007WO2006114064A3 Use of compounds to enhance processivity of telomerase
06/28/2007WO2006113703A3 Carboline derivatives useful in the treatment of cancer
06/28/2007WO2006110655A3 Compounds, compositions and methods for the treatment of poxvirus infections
06/28/2007WO2006104913A3 USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
06/28/2007WO2006099233B1 Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
06/28/2007WO2006096426A3 Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
06/28/2007WO2006091885A3 A registry method and control system for dea schedule ii-v medicines
06/28/2007WO2006090385A3 Protease inhibitors and method of screening thereof
06/28/2007WO2006089070A3 Acne gel
06/28/2007WO2006085987A3 Rna interference in respiratory epitheial cells
06/28/2007WO2006084073A3 Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
06/28/2007WO2006076681A3 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
06/28/2007WO2006071685A3 Antimicrobial combination therapy comprising an antibiotic and toxic compound selected from dna damaging agents, alkylating agents, heavy metal containing compounds and chelating agents
06/28/2007WO2006060507A9 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
06/28/2007WO2006052718A3 Farnesyltransferase inhibitors for treating sepsis
06/28/2007WO2006029155A3 Improved ghb compositions
06/28/2007WO2006029115A3 2-amino 1h imidazo ring systems and methods
06/28/2007WO2006010118A3 Conformationally constrained smac mimetics and the uses thereof
06/28/2007WO2006009698A3 Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
06/28/2007WO2005120465A3 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
06/28/2007WO2005113601A8 Antibodies and molecules derived therefrom that bind to steap-1 proteins
06/28/2007WO2005055944A3 Oligosaccharide compositions and use thereof in the treatment of infection
06/28/2007WO2005054437A3 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitor of type i and/or type ii phosphodiesterases
06/28/2007WO2005053637A3 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin
06/28/2007WO2005027839A3 Methods and reagents for the treatment of immunoinflammatory disorders
06/28/2007WO2004075850A3 Polyvalent immunogen
06/28/2007WO2004000210A3 Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
06/28/2007WO2002083919A3 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
06/28/2007US20070149916 Dry matrices as drug reservoirs in electrotransport applications
06/28/2007US20070149810 Vitamin d receptor modulators
06/28/2007US20070149782 Methods of preparing a crystalline form of 7-(4-chlorobutoxy)-3,4-dihydro-2(1h)-quinolinone and the use thereof in the synthesis of Aripiprazole
06/28/2007US20070149769 Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
06/28/2007US20070149623 a mixture of catechol, croconic acid and/or sulfites, tetrahydroxyquinone and/or sulfites and acetogenins, in the form of a tablet, a capsule, a liquids, transdermal patches and gels, used for the treatment of colon cancer, autoimmune disease and viral diseases
06/28/2007US20070149622 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
06/28/2007US20070149621 e.g. 4-[17a beta -hydroxy-17a alpha -(methoxymethyl)-17a-homo-3-oxooestra-4,9-dien-11 beta -yl]benzaldehyde (1E)-oxime;glucocorticoid receptor antagonist; androgen deficiency induced by glucocorticoids, especially cortisol; sexual dysfunction or infertility
06/28/2007US20070149620 Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea
06/28/2007US20070149619 Anti-aging agent
06/28/2007US20070149618 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
06/28/2007US20070149617 Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
06/28/2007US20070149616 C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
06/28/2007US20070149615 Ketone compounds and compositions for cholesterol management and related uses
06/28/2007US20070149614 Guanidine and amidine acid derivatives and analogs and methods of using the same
06/28/2007US20070149613 Fumagillol derivative and the medical use thereof
06/28/2007US20070149612 6-fluorochroman derivatives as chemical intermediates for preparing Nebivolol; adrenergic beta-antagonist, an antihypertensive agent, anticoagulants and a vasodilating agent; low cost, improved overall yield
06/28/2007US20070149611 Cb-delta8-thc composition
06/28/2007US20070149610 Novel compounds from garcinia hanburyi, their use in treating cancer and method of separating epimers thereof
06/28/2007US20070149609 Di(amido-substituted)heteroarene compounds as osteoblastogenesis agents
06/28/2007US20070149608 3-(4-Benzyloxyphenyl) propanoic acid derivatives
06/28/2007US20070149607 Method for producing pyrrolidine derivative
06/28/2007US20070149606 Process for producing phenylacetic acid derivative
06/28/2007US20070149605 Substituted pyrrole derivatives as hmg-coa reductase inhibitors
06/28/2007US20070149604 Novel method for preparation of crystalline perindopril erbumine
06/28/2007US20070149603 Ppar active compounds
06/28/2007US20070149602 exhibit an in vitro and in vivo antagonist activity for receptors of TRPV1 (Transient receptor potential vanilloid) (or VR1) type; pain and irritation of the skin, eyes and mucous membrane;
06/28/2007US20070149601 Bis-indole pyrroles useful as antimicrobials agents
06/28/2007US20070149600 Substituted octahydroisoindoles
06/28/2007US20070149599 Polymorphs of bicifadine hydrochloride
06/28/2007US20070149598 M3 muscarinic acetylcholine receptor antagonists
06/28/2007US20070149597 Medicinal composition as immunosuppressant
06/28/2007US20070149596 Pyrrole derivatives, their preparation and their therapeutic use
06/28/2007US20070149595 Compounds having lysophosphatidic acid receptor antagonism and uses thereof
06/28/2007US20070149594 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors
06/28/2007US20070149593 PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
06/28/2007US20070149592 Targeting gli proteins in human cancer by small molecules
06/28/2007US20070149591 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
06/28/2007US20070149590 Controlled release dosage form of pirazole compounds
06/28/2007US20070149589 Process for the Preparation of 4-(benzimidazolylmethylamino)benzamidines